Chaowei Ren

393 Middle Huaxia Road
Pudong, 201210, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Corrigendum to "Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation" [Eur. J. Med. Chem. 223 (2021) 11-05 113645].

Corrigendum to "Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation" [Eur. J. Med. Chem. 223 (2021) 11-05 113645].

Journal: European journal of medicinal chemistry

Published: March 29, 2023

Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators.

Design, synthesis and biological evaluation of novel quinazolinone derivatives as CRBN E3 ligase modulators.

Journal: European journal of medicinal chemistry

Published: September 25, 2022

Reactive oxygen species-responsive Pre-PROTAC for tumor-specific protein degradation.

Reactive oxygen species-responsive Pre-PROTAC for tumor-specific protein degradation.

Journal: Chemical communications (Cambridge, England)

Published: August 22, 2022

Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor.

Discovery and characterization of novel potent BCR-ABL degraders by conjugating allosteric inhibitor.

Journal: European journal of medicinal chemistry

Published: June 23, 2022

Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile.

Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile.

Journal: Journal of medicinal chemistry

Published: June 17, 2021

Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.

Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.

Journal: European journal of medicinal chemistry

Published: April 02, 2021

Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib.

Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib.

Journal: European journal of medicinal chemistry

Published: December 17, 2020

Construction of an IMiD-based azide library as a kit for PROTAC research.

Construction of an IMiD-based azide library as a kit for PROTAC research.

Journal: Organic & biomolecular chemistry

Published: November 23, 2020

Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.

Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.

Journal: European journal of medicinal chemistry

Published: December 17, 2019

Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.

Discovery of SIAIS178 as an Effective BCR-ABL Degrader by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.

Journal: Journal of medicinal chemistry

Published: September 21, 2019

Showing 1-10 of 10

Last Updated: 09/26/2026